3,217 Shares in Masimo Co. (NASDAQ:MASI) Acquired by Farringdon Capital Ltd.

Farringdon Capital Ltd. acquired a new position in shares of Masimo Co. (NASDAQ:MASI - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 3,217 shares of the medical equipment provider's stock, valued at approximately $532,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Marshall Wace LLP bought a new stake in shares of Masimo in the fourth quarter valued at about $2,197,000. Zacks Investment Management raised its holdings in shares of Masimo by 2.5% in the 4th quarter. Zacks Investment Management now owns 27,229 shares of the medical equipment provider's stock valued at $4,501,000 after purchasing an additional 671 shares in the last quarter. Bridgewater Associates LP increased its holdings in Masimo by 49.5% during the fourth quarter. Bridgewater Associates LP now owns 11,391 shares of the medical equipment provider's stock valued at $1,883,000 after buying an additional 3,774 shares during the period. Guggenheim Capital LLC raised its stake in Masimo by 61.5% in the fourth quarter. Guggenheim Capital LLC now owns 7,021 shares of the medical equipment provider's stock worth $1,161,000 after buying an additional 2,674 shares in the last quarter. Finally, Mariner LLC increased its holdings in shares of Masimo by 10.2% in the 4th quarter. Mariner LLC now owns 3,459 shares of the medical equipment provider's stock valued at $572,000 after acquiring an additional 321 shares during the period. 85.96% of the stock is owned by institutional investors.

Masimo Price Performance

Shares of Masimo stock traded up $7.65 on Wednesday, reaching $159.72. The company's stock had a trading volume of 192,501 shares, compared to its average volume of 657,601. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $8.63 billion, a P/E ratio of 110.15 and a beta of 1.28. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The stock has a 50-day moving average price of $166.89 and a 200-day moving average price of $165.11.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. The firm had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Analysts expect that Masimo Co. will post 4.1 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MASI shares. Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Piper Sandler upped their price objective on shares of Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Raymond James boosted their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research report on Friday, December 27th. Finally, Wells Fargo & Company lifted their price objective on shares of Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $194.80.

Insiders Place Their Bets

In other news, COO Bilal Muhsin sold 30,000 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the transaction, the chief operating officer now owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the transaction, the director now directly owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by corporate insiders.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.